InsiderClue
Stocks · Health care · Pharmaceutical Preparations

GT Biopharma, Inc.

GTBP Clue Score29
United States Fiscal year ends December CIK 0000109657
$6.68 +12.08% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $6.68 +10.05% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 22 Sep 2017. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2016Revenue0.0Operating income−9.4Net income9.8EPS, diluted119.91Fiscal year 2017Revenue0.0Operating income−135.6Net income−144.2 −1,576.0%EPS, diluted−8.60Fiscal year 2018Operating income−250.1Net income−259.2EPS, diluted−5.16Fiscal year 2019Revenue0.0Operating income16.1Net income−38.6Fiscal year 2020Revenue0.0Operating income−6.8Net income−28.3Fiscal year 2021Operating income−57.5Net income−58.0Fiscal year 2022Operating income−21.3Net income−20.9EPS, diluted−19.66Fiscal year 2023Operating income−13.6Net income−7.6EPS, diluted−5.64Fiscal year 2024Operating income−14.4Net income−13.2EPS, diluted−6.94Fiscal year 2025Operating income−12.4Net income−28.4EPS, diluted−6.68
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue 0.0 0.0 n/a 0.0 0.0 n/a n/a n/a n/a n/a
Growth
Operating income −9.4 −135.6 −250.1 16.1 −6.8 −57.5 −21.3 −13.6 −14.4 −12.4
Net income 9.8 −144.2 −259.2 −38.6 −28.3 −58.0 −20.9 −7.6 −13.2 −28.4
Growth −1,576.0%
EPS, diluted 119.91 −8.60 −5.16 n/a n/a n/a −19.66 −5.64 −6.94 −6.68

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2016Operating cash flow−1.9Capital expenditure0.0Free cash flow−1.9Fiscal year 2017Operating cash flow−5.4Capital expenditure−0.0Free cash flow−5.4Fiscal year 2018Operating cash flow−10.7Capital expenditure−0.0Free cash flow−10.7Fiscal year 2019Operating cash flow−3.7Capital expenditure0.0Free cash flow−3.7Fiscal year 2020Operating cash flow−7.3Fiscal year 2021Operating cash flow−15.6Fiscal year 2022Operating cash flow−15.2Fiscal year 2023Operating cash flow−8.9Fiscal year 2024Operating cash flow−12.9Fiscal year 2025Operating cash flow−12.9Dividends paid−0.2
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −1.9 −5.4 −10.7 −3.7 −7.3 −15.6 −15.2 −8.9 −12.9 −12.9
Capital expenditure 0.0 −0.0 −0.0 0.0 n/a n/a n/a n/a n/a n/a
Free cash flow −1.9 −5.4 −10.7 −3.7 n/a n/a n/a n/a n/a n/a
Growth
Dividends paid n/a n/a n/a n/a n/a n/a n/a n/a n/a −0.2

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2016Cash0.0Shareholders’ equity−18.9Fiscal year 2017Cash0.6Shareholders’ equity251.7Fiscal year 2018Cash0.1Shareholders’ equity11.4Fiscal year 2019Cash0.0Shareholders’ equity−19.3Fiscal year 2020Cash5.3Shareholders’ equity−29.4Fiscal year 2021Cash9.0Shareholders’ equity21.9Fiscal year 2022Cash5.7Shareholders’ equity11.7Fiscal year 2023Cash1.1Shareholders’ equity7.5Fiscal year 2024Cash4.0Shareholders’ equity−1.7Fiscal year 2025Cash6.8Shareholders’ equity5.8
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 0.0 0.6 0.1 0.0 5.3 9.0 5.7 1.1 4.0 6.8
Shareholders’ equity −18.9 251.7 11.4 −19.3 −29.4 21.9 11.7 7.5 −1.7 5.8

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2016 31 Dec 2016 FY2017† 31 Dec 2017 FY2018† 31 Dec 2018 FY2019† 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022† 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025† 31 Dec 2025
Revenue and profit
0.0 0.0 n/a 0.0 0.0 n/a n/a n/a n/a n/a
Growth
0.0 0.0 n/a n/a n/a n/a n/a n/a n/a n/a
0.0 0.0 n/a n/a n/a n/a n/a n/a n/a n/a
Growth
1.0 1.1 9.1 1.7 0.5 9.6 8.8 6.5 5.8 3.5
8.4 134.5 12.5 9.8 6.3 47.9 12.4 7.1 8.6 9.0
−9.4 −135.6 −250.1 16.1 −6.8 −57.5 −21.3 −13.6 −14.4 −12.4
Growth −142.1%
9.8 −144.2 −259.2 −38.6 n/a n/a n/a n/a n/a n/a
0.0 0.0 0.0 0.0 n/a n/a n/a n/a n/a n/a
9.8 −144.2 −259.2 −38.6 −28.3 −58.0 −20.9 −7.6 −13.2 −28.4
Growth −1,576.0%
Per share
119.91 −8.60 −5.16 n/a n/a −2.06 −19.66 −5.64 −6.94 −6.68
119.91 −8.60 −5.16 n/a n/a n/a −19.66 −5.64 −6.94 −6.68
Growth −107.2%
0.1 0.0 0.1 n/a n/a 28.2 1.1 1.3 1.9 5.5
0.1 0.0 0.1 3.4 4.4 n/a 1.1 1.3 1.9 5.5
Growth −79.4% +199.6% +6,635.6% +29.6% +26.9% +40.8% +190.6%

† The diluted share count jumps at 2017 and 2018 and 2019 and 2022 and 2025, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 9 of 10 years on file.